Contact
searchSearch
HMP Global
Quiz

Which factors increase the risk of late-onset epilepsy (LOE) in people with cognitive decline?

04/23/2025

News

Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
FDA approval stamp
News
FDA Approves Diazepam Nasal Spray for Children Aged 2 to 5 With Seizure Clusters
04/16/2025
Meagan Thistle
The FDA has expanded approval of immediate-use diazepam nasal spray as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity—also known as seizure clusters or acute repetitive seizures—in pediatric patients...
The FDA has expanded approval of immediate-use diazepam nasal spray as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity—also known as seizure clusters or acute repetitive seizures—in pediatric patients...
The FDA has expanded approval of...
04/16/2025
Neurology
older woman on bed rest
News
Olfactory Deficits Signal Mortality Risk From Neurodegenerative Causes in Older Adults
04/14/2025
Jolynn Tumolo
Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
Each additional incorrect answer...
04/14/2025
Neurology
image of the heart
News
After Stroke in Atrial Fibrillation, Earlier Oral Anticoagulant Initiation Appears Better
04/07/2025
Jolynn Tumolo
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
A clinical trial that...
04/07/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
illustrated brain with brain waves against a black background
News
Tool Gauges a Patient’s Epilepsy Status From a Single Normal EEG
03/12/2025
Jolynn Tumolo
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
A newly developed tool uses...
03/12/2025
Neurology
fda building sign
News
FDA Approves First New Stroke Drug, Tenecteplase, in Nearly 30 Years
03/04/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
The US Food and Drug...
03/04/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
FDA Approves ‘Self-Adjusting’ DBS Therapy for Parkinson Disease
02/25/2025
Brionna Mendoza
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use